TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24569324

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 21865154

Group type: EXPERIMENTAL
Intervention: Dietary intervention (specific details not provided)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Recruitment strategies (hand distributed letters, flyers, word of mouth)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Overall recruitment process
Number of subjects: 333
Study: 19144173

Group type: COMPARATOR
Intervention: Long-acting anticholinergics
Number of subjects: 26786

Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 26786

Group type: COMPARATOR
Intervention: Long-acting bronchodilators alone
Number of subjects: 26786

Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 26786

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and combination treatment
Number of subjects: 26786
Study: 17461719

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily with gastric acid-reducing agents
Number of subjects: 228

Group type: COMPARATOR
Intervention: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily without gastric acid-reducing agents
Number of subjects: 228
Study: 15610362

Group type: EXPERIMENTAL
Intervention: High dose birch pollen exposure during pregnancy
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Low dose birch pollen exposure during pregnancy
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Maternal birch sensitization
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Maternal pollen allergy
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Asthma symptoms and sensitization to birch
Number of subjects: 387
Study: 11310807

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (2 g/200 mg/8 hr)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ceftriaxone (1 g/24 hr)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 378
Study: 9153524

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study: 8389105

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (200 micrograms/puff, total dose 1,600 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (propellant alone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 204,219
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3818718

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 55
Study: 29374679

Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 1128

Group type: COMPARATOR
Intervention: X-Bolt Dynamic Hip Plating System
Number of subjects: 1128
Study: 27472878

Group type: EXPERIMENTAL
Intervention: Crocus sativus L.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 35
Study: 25300433

Group type: EXPERIMENTAL
Intervention: FAST intervention - systematic and progressive practice of fast squatting and stepping exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control - conventional physiotherapy directed at improving balance and mobility that includes no targeted fast movement training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FAST intervention
Number of subjects: 60
Study: 22325963

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB) with 0.2% ropivacaine via indwelling catheter for 72 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multimodal periarticular soft tissue injection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Functional outcomes
Number of subjects: 16
Study: 20052813

Group type: EXPERIMENTAL
Intervention: Selective approach (group SEL) - only the nerves involved in the surgical field were injected
Number of subjects: 414

Group type: COMPARATOR
Intervention: Standard triple-nerve stimulation technique (group TNS)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Selective approach (group SEL)
Number of subjects: 414
Study: 17280925

Group type: EXPERIMENTAL
Intervention: 0.4 ml fentanyl 0.05 mg/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.4 ml mepivacaine with epinephrine 1:200,000
Number of subjects: 40
Study: 15663351

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 or 2mg once daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 or 1mg once daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline 1mg once daily
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline (monotherapy and combination therapy)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline for 12 months
Number of subjects: 404
Study: 12360588

Group type: EXPERIMENTAL
Intervention: Transluminal balloon coronary angioplasty (TBCA) or stenting
Number of subjects: 87
Study: 9988823

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (without zinc)
Number of subjects: 55
Study: 7502571

Group type: EXPERIMENTAL
Intervention: VVIR1-pacing (70-110 bpm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VVIR2-pacing (70-130 bpm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VVIR1-pacing (70-110 bpm) in Weber class D patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VVIR2-pacing (70-130 bpm) in Weber class C patients
Number of subjects: 20
Study: 1575174

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 50 mg
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 100 mg
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 150 mg
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 3893441

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 30169375

Group type: EXPERIMENTAL
Intervention: Concurrent pictorial drug choice task (smoking vs. not smoking)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Concurrent pictorial drug choice task (alcohol vs. food)
Number of subjects: 81
Study: 26390226

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 30
Study: 26327217

Group type: EXPERIMENTAL
Intervention: Home-assessment group
Number of subjects: 731

Group type: COMPARATOR
Intervention: Clinic follow-up group
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 731
Study: 23897964

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 21046236

Group type: EXPERIMENTAL
Intervention: Diet FO (fish oil)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet LO (linseed oil)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet SO (soybean oil)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diet PO (peanut oil)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet PL (pork lard)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diet APO (arachidonic acid and peanut oil)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diets with EPA and DHA
Number of subjects: 6
Study: 18773262

Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol, twice daily for 3 years
Number of subjects: 146

Group type: COMPARATOR
Intervention: 0.5% timolol ophthalmic solution, twice daily for 3 years
Number of subjects: 146
Study: 16523203

Group type: EXPERIMENTAL
Intervention: Barley kernels
Number of subjects: 15

Group type: COMPARATOR
Intervention: WWB
Number of subjects: 15
Study: 14669936

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplement (18 mg beta‐carotene, 900 mg vitamin C, 90 mg vitamin E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplement
Number of subjects: 12
Study: 10844841

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 21
Study: 8705154

Group type: EXPERIMENTAL
Intervention: 3 mg intra-articular morphine in 15 ml isotonic saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mg intravenous morphine in 10 ml isotonic saline
Number of subjects: 60
Study: 2371491

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg/day for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 453340

Group type: EXPERIMENTAL
Intervention: Auditory electromyographic (EMG) feedback applied at 6, 25, 30, 49, and 54 hours after exercise.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Static stretching applied to the exercised arm at 6, 25, 30, 49, and 54 hours after exercise.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 36
Study: 29610222

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL) followed by photorefractive keratectomy (PRK) after 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: PRK alone
Number of subjects: 44
Study: 28176907

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 µg
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 24989711

Group type: EXPERIMENTAL
Intervention: Transfusion‐dependent β‐thalassemia patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with evident heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with β‐thalassemia
Number of subjects: 0
Study: 22420837

Group type: EXPERIMENTAL
Intervention: Saline-soaked antibacterial gauze-based NPWT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional antiseptic (polyhexanide solution) dressings
Number of subjects: 50
Study: 22403988

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief Toothpaste
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sensodyne Rapid Relief Toothpaste
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Crest Cavity Protection Toothpaste
Number of subjects: 150
Study: 19486346

Group type: EXPERIMENTAL
Intervention: m-TOR inhibitor sirolimus (SRL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CNI treatment
Number of subjects: 16
Study: 16855426

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 4 mg/24 h weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h starting dose, increased by 2 mg/24 h weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast-titration regimen of rotigotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-titration regimen of rotigotine
Number of subjects: 0
Study: 12944032

Group type: EXPERIMENTAL
Intervention: Nisoldipine ER (20 to 60 mg once daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Amlodipine (5 to 10 mg once daily)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nisoldipine ER
Number of subjects: 192

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nisoldipine ER and Amlodipine
Number of subjects: 192
Study: 11151420

Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: selegiline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 60
Study: 9088588

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily for 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8491252

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol 150 mg
Number of subjects: 8
Study: 3438883

Group type: EXPERIMENTAL
Intervention: Hyperosmolar saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 20
Study: 29362244

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) plus standard oncologic care
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 480
Study: 26322917

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid (O3FA) oral supplement (2,400 mg/day) for 45 days
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo (olive oil, 8 capsules)
Number of subjects: 256
Study: 25404192

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3883
Study: 23695483

Group type: EXPERIMENTAL
Intervention: Escitalopram (5 mg/d titrated to 20 mg/d over 6 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 127
Study: 20584124

Group type: EXPERIMENTAL
Intervention: PSD502
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 18261166

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1800 mg daily from day 4 to day 14
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 101
Study: 16173532

Group type: EXPERIMENTAL
Intervention: External Qi therapy (EQT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control therapy
Number of subjects: 30
Study: 12921918

Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg/day (under 5 years) and 10 mg/day (over 5 years)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Methylphenidate 1 mg/kg/day
Number of subjects: 28
Study: 10937097

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser treatment followed by erbium:YAG laser treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser treatment alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser treatment followed by carbon dioxide laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated skin subjected to laser treatment
Number of subjects: 10
Study: 8669575

Group type: EXPERIMENTAL
Intervention: 20 ml bupivacaine 0.5% + 25 mg (0.5 ml) ketamine + 1 in 200,000 adrenaline
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 ml bupivacaine 0.5% + 0.5 ml 0.9% saline + 1 in 200,000 adrenaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 1705348

Group type: EXPERIMENTAL
Intervention: Hospital-based case management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional discharge and follow-up services of a NICU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition model (additional 7% referred)
Number of subjects: 0
Study: 6721765

Group type: EXPERIMENTAL
Intervention: Half-strength povidone-iodine (Betadine) solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (second eye)
Number of subjects: 30
Study: 30859938

Group type: COMPARATOR
Intervention: BUP/SAM 2mg/2mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BUP/SAM 8mg/8mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BUP/SAM 16mg/16mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BUP alone 8mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BUP alone 16mg
Number of subjects: 38
Study: 30006669

Group type: EXPERIMENTAL
Intervention: Trunk fatigue
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (rest period)
Number of subjects: 16
Study: 27257288

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Pregabalin (both dosages)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1665
Study: 24305572

Group type: EXPERIMENTAL
Intervention: Multiple group sessions for IDUs and family members
Number of subjects: 166
Study: 22976741

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) - aerobic training program (3-4 sessions/week, 50 min/session, at 70% maximum heart rate)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) - aerobic training program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 43
Study: 19250071

Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 8 weeks
Number of subjects: 41
Study: 17309381

Group type: EXPERIMENTAL
Intervention: Wet cupping (treated group, N = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (untreated group, N = 24)
Number of subjects: 47
Study: 15201136

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 114
Study: 11531671

Group type: EXPERIMENTAL
Intervention: 5000 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 7500 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10,000 U unfractionated heparin subcutaneously after surgery
Number of subjects: 23
Study: 9846590

Group type: EXPERIMENTAL
Intervention: autoclaved retrograded high-amylose corn starch (HACS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: drum-dried ordinary corn starch
Number of subjects: 7
Study: 7985709

Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B (0.1 mg/kg per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2728961

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 131

Group type: COMPARATOR
Intervention: Behavioral training alone
Number of subjects: 131
Study: 30689597

Group type: EXPERIMENTAL
Intervention: Electric Adjustable Height Desks (EAHD)
Number of subjects: 0
Study: 29208686

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (20 μg/kg sc 3×/week) for 26 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 72
Study: 25524023

Group type: EXPERIMENTAL
Intervention: Alendronate/cholecalciferol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 30
Study: 24693681

Group type: EXPERIMENTAL
Intervention: Antioxidant nutrients supplement (AO) for 5 days prior to surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CT) with no supplement
Number of subjects: 23
Study: 20801521

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Risk score (15-point GA risk score)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Risk score (5-factor risk score)
Number of subjects: 1052
Study: 19546522

Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA) 2.5 mg/kg body weight
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ciclosporine (CsA) and Mycophenolate mofetil (MMF)
Number of subjects: 54
Study: 16682258

Group type: EXPERIMENTAL
Intervention: Polymeric formula
Number of subjects: 37

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 37
Study: 15474755

Group type: EXPERIMENTAL
Intervention: CE/MPA (conjugated estrogen 0.625 mg + medroxyprogesterone acetate 5 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E2/NETA (17‐beta‐estradiol 2 mg + norethisterone acetate 1 mg)
Number of subjects: 92
Study: 11374601

Group type: EXPERIMENTAL
Intervention: Isoflurane at 37 degrees C
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Isoflurane at 34 degrees C
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Isoflurane at 31 degrees C
Number of subjects: 33
Study: 9247524

Group type: EXPERIMENTAL
Intervention: DM (DDDR with mode switching)
Number of subjects: 48

Group type: COMPARATOR
Intervention: VR (VVIR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: DR (DDDR with conventional upper rate behavior)
Number of subjects: 48
Study: 8295016

Group type: EXPERIMENTAL
Intervention: Warm water immersion (WI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No warm water immersion (no-WI)
Number of subjects: 93
Study: 2436359

Group type: EXPERIMENTAL
Intervention: Glycerol therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination therapy of glycerol and dextran
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 28826262

Group type: EXPERIMENTAL
Intervention: Topical propolis ointment (5%; twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies alone
Number of subjects: 0
Study: 27583920

Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional analgesia (n = 22)
Number of subjects: 45
Study: 24841843

Group type: EXPERIMENTAL
Intervention: Cocaine exposure (40 mg, IV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22279132

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 55
Study: 20332738

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg . kg‐1. min‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17418537

Group type: EXPERIMENTAL
Intervention: 5HT2 receptor antagonists (trazodone or nefazodone)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 988